FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thomas Ciossek

Research Profile

Chemicals & Drugs

Phenomena

Acetylation

Anatomy

Concepts & Ideas

Structure-Activity Relationship

Procedures

Co-author Network

Publications

TOP 3
Siavosh Mahboobi; Andreas Sellmer; Matthias Winkler; Emerich Eichhorn; Herwig Pongratz; Thomas Ciossek; Thomas Baer; Thomas Maier; Thomas Beckers
Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
Siavosh Mahboobi; Stefan Dove; Andreas Sellmer; Matthias Winkler; Emerich Eichhorn; Herwig Pongratz; Thomas Ciossek; Thomas Baer; Thomas Maier; Thomas Beckers
Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
Florian Dehmel; Steffen Weinbrenner; Heiko Julius; Thomas Ciossek; Thomas Maier; Thomas Stengel; Kamal Fettis; Carmen Burkhardt; Heike Wieland; Thomas Beckers
Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thomas Ciossek (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Siavosh Mahboobi; Andreas Sellmer; Matthias Winkler; Emerich Eichhorn; Herwig Pongratz; Thomas Ciossek; Thomas Baer; Thomas Maier; Thomas Beckers
Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
Journal of medicinal chemistry 2010;53(24):8546-55.
2009: Siavosh Mahboobi; Stefan Dove; Andreas Sellmer; Matthias Winkler; Emerich Eichhorn; Herwig Pongratz; Thomas Ciossek; Thomas Baer; Thomas Maier; Thomas Beckers
Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
Journal of medicinal chemistry 2009;52(8):2265-79.
2008: Florian Dehmel; Steffen Weinbrenner; Heiko Julius; Thomas Ciossek; Thomas Maier; Thomas Stengel; Kamal Fettis; Carmen Burkhardt; Heike Wieland; Thomas Beckers
Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles.
Journal of medicinal chemistry 2008;51(13):3985-4001.
2008: Thomas Ciossek; Heiko Julius; Heike Wieland; Thomas Maier; Thomas Beckers
A homogeneous cellular histone deacetylase assay suitable for compound profiling and robotic screening.
Analytical biochemistry 2008;372(1):72-81.
2007: Siavosh Mahboobi; Andreas Sellmer; Heymo Höcher; Christian Garhammer; Herwig Pongratz; Thomas Maier; Thomas Ciossek; Thomas Beckers
2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
Journal of medicinal chemistry 2007;50(18):4405-18.
2007: Florian Dehmel; Thomas Ciossek; Thomas Maier; Steffen Weinbrenner; Beate Schmidt; Martin Zoche; Thomas Beckers
Trithiocarbonates: exploration of a new head group for HDAC inhibitors.
Bioorganic & medicinal chemistry letters 2007;17(17):4746-52.
2007: Thomas Beckers; Carmen Burkhardt; Heike Wieland; Petra Gimmnich; Thomas Ciossek; Thomas Maier; Karl Sanders
Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group.
International journal of cancer. Journal international du cancer 2007;121(5):1138-48.
2005: Tahira Rashid; A Louise Upton; Aida Blentic; Thomas Ciossek; Bernd Knöll; Ian D Thompson; Uwe Drescher
Opposing gradients of ephrin-As and EphA7 in the superior colliculus are essential for topographic mapping in the mammalian visual system.
Neuron 2005;47(1):57-69.
2003: Audrey Dufour; Julie Seibt; Lara Passante; Vanessa Depaepe; Thomas Ciossek; Jonas Frisén; Klas Kullander; John G Flanagan; Franck Polleux; Pierre Vanderhaeghen
Area specificity and topography of thalamocortical projections are controlled by ephrin/Eph genes.
Neuron 2003;39(3):453-65.
2003: Thomas Häder; Sandra Müller; Miguel Aguilera; Karsten Eulenberg; Arnd Steuernagel; Thomas Ciossek; Ronald P Kühnlein; Lydia Lemaire; Rüdiger Fritsch; Cord Dohrmann; Ingrid R Vetter; Herbert Jäckle; Winifred W Doane; Günter Brönner
Control of triglyceride storage by a WD40/TPR-domain protein.
EMBO reports 2003;4(5):511-6.
2000: S Wahl; H Barth; Thomas Ciossek; K Aktories; Bernhard K Mueller
Ephrin-A5 induces collapse of growth cones by activating Rho and Rho kinase.
The Journal of cell biology 2000;149(2):263-70.
1999: Martin R Hornberger; D Dütting; Thomas Ciossek; T Yamada; C Handwerker; Susanne Lang; F Weth; J Huf; R Wessel; C Logan; Hideaki Tanaka; Uwe Drescher
Modulation of EphA receptor function by coexpressed ephrinA ligands on retinal ganglion cell axons.
Neuron 1999;22(4):731-42.
1998: Thomas Ciossek; B Monschau; C Kremoser; Jürgen Löschinger; Susanne Lang; BK Müller; Friedrich Bonhoeffer; Uwe Drescher
Eph receptor-ligand interactions are necessary for guidance of retinal ganglion cell axons in vitro.
The European journal of neuroscience 1998;10(5):1574-80.